BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Severe Hypertriglyceridemia readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Severe Hypertriglycer
 idemia\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07269210-1093@assetmemo.bio
DTSTAMP:20261121T004500Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Solbinsiran: Phase 2 readout est. (NCT07269210)
DESCRIPTION:Solbinsiran\, phase 2\, Atherosclerotic Cardiovascular Disease.
 \nStudy: A Study of Solbinsiran (LY3561774) in Participants With Severe Hy
 pertriglyceridemia\nEstimated primary completion: March 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/solbinsiran#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07269210
URL:https://assetmemo.bio/drug/solbinsiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05681351-1044@assetmemo.bio
DTSTAMP:20261121T004500Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Tryngolza (Olezarsen): Phase 3 readout est. (NCT05681351)
DESCRIPTION:Tryngolza (Olezarsen)\, phase 3\, Severe Hypertriglyceridemia.\
 nStudy: CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutan
 eously to Participants With Severe Hypertriglyceridemia (SHTG)\nEstimated 
 primary completion: March 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/olezarsen#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05681351
URL:https://assetmemo.bio/drug/olezarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07308392-1208@assetmemo.bio
DTSTAMP:20261121T004500Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:HRS-7249: Phase 2 readout est. (NCT07308392)
DESCRIPTION:HRS-7249\, phase 2\, Severe Hypertriglyceridemia.\nStudy: Phase
  II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-
 1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pa
 ncreatitis\nEstimated primary completion: June 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/hrs-7249#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07308392
URL:https://assetmemo.bio/drug/hrs-7249#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07604974-1085@assetmemo.bio
DTSTAMP:20261121T004500Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:ION775: Phase 2 readout est. (NCT07604974)
DESCRIPTION:ION775\, phase 2\, Severe Hypertriglyceridemia.\nStudy: A Study
  to Assess the Safety\, Tolerability and Efficacy of ION775\nEstimated pri
 mary completion: September 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ion775#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07604974
URL:https://assetmemo.bio/drug/ion775#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07693777-228@assetmemo.bio
DTSTAMP:20261121T004500Z
DTSTART;VALUE=DATE:20290214
DTEND;VALUE=DATE:20290215
SUMMARY:DR10624: Phase 3 readout est. (NCT07693777)
DESCRIPTION:DR10624\, phase 3\, Severe Hypertriglyceridemia.\nStudy: A Phas
 e III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects 
 With Severe Hypertriglyceridemia\nEstimated primary completion: 14 Februar
 y 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/dr10624#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07693777
URL:https://assetmemo.bio/drug/dr10624#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06880770-1043@assetmemo.bio
DTSTAMP:20261121T004500Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Redemplo (Plozasiran): Phase 3 readout est. (NCT06880770)
DESCRIPTION:Redemplo (Plozasiran)\, phase 3\, Severe Hypertriglyceridemia.\
 nStudy: Study of Plozasiran in Adults With Severe Hypertriglyceridemia at 
 Risk of Acute Pancreatitis\nEstimated primary completion: March 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/plozasiran#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06880770
URL:https://assetmemo.bio/drug/plozasiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07680829-228@assetmemo.bio
DTSTAMP:20261121T004500Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:DR10624: Phase 3 readout est. (NCT07680829)
DESCRIPTION:DR10624\, phase 3\, Severe Hypertriglyceridemia.\nStudy: A Phas
 e 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglycer
 idemia\nEstimated primary completion: June 2030. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/dr10624#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07680829
URL:https://assetmemo.bio/drug/dr10624#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
